CVS
CVS Health Corporation
CVS has the edge over OSCR overall, supported by stronger valuation and lower modeled downside.
OSCR
Oscar Health, Inc.
OSCR offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
CVS Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Stable |
CVS's profitability and cash flow are currently healthy, and its revenue and balance sheet are stable.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
CVS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $89.79 | — |
| Cheap | 11x | $97.03 | +8.1% |
| Forward | 11x | $89.79 | — |
| Fair | 16x | $137 | +53% |
| Expensive | 29x | $254 | +182% |
Historical ranges are pointers, not guarantees.
CVS's PE is in its cheap range at 10x. On analysts' estimates for next year's earnings, today's price would be 11x.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over CVS in the historical PE scenario, which offers more potential upside but is not a forecast.
CVS Forward outlook
| Metric | Outlook |
|---|---|
| Stable | |
| Strong growth | |
| Growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect earnings and revenue growth for CVS, with profitability holding steady. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over CVS on the outlook, with more favorable valuation and profitability expectations.
CVS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $8.46 | -1.6% |
| Q3 2026 | $8.60 | +2163% |
| Q2 2026 | $3.79 | +5.9% |
| Q1 2026 | $2.28 | -46% |
| Q4 2025 | $1.39 | -62% |
| Q3 2025 | $0.38 | -90% |
| Q2 2025 | $3.58 | -36% |
| Q1 2025 | $4.19 | -26% |
| Q4 2024 | $3.66 | -43% |
CVS's earnings per share have jumped to their highest in seven years: $8.60 over the past year, up from $0.38 the year before.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over CVS on earnings, with more consistent year-over-year improvement.
CVS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $108.4B | +5.4% |
| Q2 2026 | $106.1B | +7.3% |
| Q1 2026 | $100.4B | +6.2% |
| Q4 2025 | $105.7B | +8.2% |
| Q3 2025 | $102.9B | +7.8% |
| Q2 2025 | $98.9B | +8.4% |
| Q1 2025 | $94.6B | +7% |
| Q4 2024 | $97.7B | +4.2% |
CVS's revenue has grown year over year every quarter since late 2020: $108B last quarter, up 5.4% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.3% | +6.4 points |
| Q2 2026 | 4.4% | +2 points |
| Q1 2026 | 4.7% | +1.1 points |
| Q4 2025 | 2% | -0.4 points |
| Q3 2025 | -3.1% | -4 points |
| Q2 2025 | 2.4% | -0.9 points |
| Q1 2025 | 3.6% | +1 points |
| Q4 2024 | 2.4% | -1.2 points |
CVS's operating margin was 3.3% last quarter, up 6.4 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over CVS on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over CVS on profitability, with a higher operating margin.
CVS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $3.9B | +3887% |
| Q2 2026 | $5.7B | +338% |
| Q1 2026 | $3.4B | -11% |
| Q4 2025 | $2.6B | +139% |
| Q3 2025 | $98M | +$1.5B |
| Q2 2025 | $1.3B | -47% |
| Q1 2025 | $3.8B | -9.2% |
| Q4 2024 | $1.1B | +$4.6B |
CVS generated $15.6B in free cash flow over the past year, up 147% from the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over CVS on cash flow, with more consistent year-over-year improvement.
CVS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +4M shares |
| 1 year | +1.7% | +22M shares |
| 3 years | +0.1% | +1M shares |
| 5 years | -2.9% | -38M shares |
| Available history | -1.1% | -14M shares |
CVS has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | $1M |
| Q2 2024 | $3M |
| Q1 2024 | $3B |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
CVS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.5x | Moderate |
| Q2 2026 | 3.9x | Elevated |
| Q1 2026 | 5.1x | High |
| Q4 2025 | 6.1x | High |
| Q3 2025 | 6.1x | High |
| Q2 2025 | 4.0x | High |
| Q1 2025 | 3.8x | Elevated |
| Q4 2024 | 4.6x | High |
CVS's net debt is about 2.5 years of its operating earnings (EBITDA), down from 6.1 years a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over CVS on leverage, with a lower net debt burden relative to earnings.
CVS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 48.6 | Neutral |
| Stochastic | 35.1 | Neutral |
CVS's weekly RSI is 49 (neutral) and its Stochastic is 35 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
CVS PE vs Healthcare Sector
| Metric | CVS | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 9 | 29 | 20 pts below |
CVS has the edge over OSCR on valuation relative to its sector.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
CVS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $88.9 | 1% above |
| 20 week MA | $95.0 | 5.4% below |
| 50 week MA | $87.6 | 2.5% above |
| 100 week MA | $77.0 | 17% above |
| 200 week MA | $72.9 | 23% above |
CVS's trend is mixed: it's above four of its five weekly moving averages, and 23% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over CVS on trend strength, trading above more of its moving averages.
CVS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $74.4 | $68.0 | -8.6% |
| 2021 | $68.0 | $101.3 | +49% |
| 2022 | $101.3 | $93.6 | -7.6% |
| 2023 | $93.6 | $79.0 | -16% |
| 2024 | $79.0 | $44.5 | -44% |
| 2025 | $44.5 | $79.6 | +79% |
| 2026 YTD | $79.6 | $89.8 | +13% |
CVS has finished lower in four of the last six years. It's up 13% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over CVS on returns for 2026, with the stronger performance.